23 results about "Deoxyribonucleotide" patented technology

The invention provides a genetically engineered bacterium for producing polydeoxyribonucleotide as well as a construction method and application of the genetically engineered bacterium. The genetically engineered bacterium comprises kluyveromyces marxianus for expressing a salmon DNA polymerase I gene. According to the invention, the edible probiotic Kluyveromyces marxianus is transformed through genetic engineering, efficient, safe and controllable production of PDRN is realized, the biological activity of PDRN is equivalent to that of PDRN from a natural source, and large-scale production and application of PDRN are facilitated.

The application provides an enhanced transdermal absorption cosmetic patch containing high-efficiency active polydeoxyribonucleotide PDRN (DNA sodium) and a low-temperature preparation method thereof. The cosmetic patch comprises, from outside to inside, an outer release backing layer, a slow-release core layer, a quick-release core layer and a soluble hollow microneedle array layer. The outer release backing layer is a PET / aluminum foil / polyethylene composite film, and the mass ratio of the three is (80-90):(0.5-2):(0.1-0.5). The PDRN is efficiently delivered transdermally, has long-term effect, high activity retention and excellent biocompatibility, and significantly improves the transdermal efficiency and use safety of the cosmetic patch.

The present invention relates to an in vitro cell-free process for production of deoxyribonucleotides (DNAs) comprising at least one hairpin, corresponding DNA products and uses thereof, and oligonucleotides and kits useful in the process of the invention.

A comprehensive teaching aid system for genetic science at least including numerous (deoxy-) ribonucleotide models that can be assembled to form DNA / RNA single strands, or to form the beautiful DNA double helix structure when numerous adjacently and oppositely connected deoxynucleotide models are attached by magnets, tRNAs, and three different plates for DNA replication, mRNA transcription and protein synthesis respectively. The (deoxy-) nucleotide model includes a phosphate model, a (deoxy-) ribose model and a base model connected in sequence. Between two adjacently disposed (deoxy-) ribonucleotide models, a (deoxy-) ribose model is connected to a phosphate model in the head-to-tail fashion to form a detachable and flexible chain structure. The base model is laterally connected to the (deoxy-) ribose model, and two base models in two oppositely disposed deoxynucleotide models are flexibly and complementarily attached.

The invention provides a DNA paper-cutting system, method and product for resisting polymerase chain displacement, and belongs to the field of DNA nanotechnology, the DNA paper-cutting system comprises: a DNA nanostructure comprising a cutting region and a non-cutting region; wherein on the template chain of the non-cutting area, a blocking sequence is arranged at the 5'end of a template chain section corresponding to at least one nicking site, and the blocking sequence is composed of one or more basic groups belonging to a target basic group type; the specific reaction buffer solution contains DNA (deoxyribonucleic acid) polymerase and a plurality of deoxyribonucleoside triphosphates except a specific deoxyribonucleoside triphosphate; wherein the type of the specific deoxyribonucleoside triphosphate deleted in the specific reaction buffer solution is complementary to the type of the target basic group.

The invention discloses a QPCR (Quantitative Polymerase Chain Reaction)-based DNA (Deoxyribose Nucleic Acid) methylation rate detection method, which comprises the following steps of: treating a DNA sample to be detected by bisulfite, dividing the DNA sample into a first sample and a second sample which are parallel to each other, and performing substrate amplification on a methylated DNA template and a non-methylated DNA template in the samples through PCR amplification by adopting the same amplification primer under the same condition; then respectively depleting dATP in a sample A reaction system and dGTP in a sample B reaction system through a template and a primer with thymine deoxyribonucleotide repetitive sequences or a template and a primer with cytosine deoxyribonucleotide repetitive sequences, and controlling independent detection of methylation and non-methylation templates through a d3TP system lacking dATP or dGTP; and finally, directly analyzing the fluorescence signal of the methylation template and the fluorescence signal of the non-methylation template, and calculating the methylation rate of the DNA sample to be detected through a methylation rate calculation function.

A method of ligating a ligation product for detecting abasic sites on DNA target sequence is described. The ligation method uses a pyrene probe that ligates with a second probe in the presence of a ligase. A pyrene may comprise 5′-phosphate 1′-pyrene deoxyribonucleotide at the 5′-terminus. The second probe may comprise a terminal 3′-hydroxy, wherein the 3′-hydroxy is ligated with the pyrene probe. The ligase may be T4 DNA Ligase or PBCV-1 as the latter has been found to improve selectivity. The abasic on the DNA target sequence may be naturally occurring or may be a generated abasic that is formed by the addition of an enzyme. Furthermore, selectivity may be increase by the addition of adenosine triphosphate (ATP) or ligating at a temperature above the probe:target sequence thermal disassociation temperature.

The invention provides a preparation method of an anti-wrinkle essence, which is used for preparing the anti-wrinkle essence comprising polydeoxyribonucleotide and human collagen which are used as anti-wrinkle agents, ribonucleic acid which is used as a neurotransmitter inhibitor, and an antioxidant, a humectant, a thickening agent, a diluent, a pH regulator and a preservative which are added in cosmetics in an acceptable manner. Comprising the following steps: putting a diluent into a preparation pot, and scattering a thickening agent carbomer; the preparation method comprises the following steps: pre-dispersing a humectant sodium hyaluronate, glycerol, butanediol and sclerotium gum serving as a thickener, adding the pre-dispersed humectant sodium hyaluronate, glycerol and butanediol into a preparation pot, stirring and heating, adding pentanediol serving as the humectant and an antioxidant, continuously stirring until the materials are uniform, and cooling for the first time; adding a pH regulator into the preparation pot subjected to primary cooling to regulate the pH value, carrying out secondary cooling, adding a preservative, a neurotransmitter inhibitor, an anti-wrinkle agent and other materials serving as a thickening agent and a humectant, continuously stirring until the materials are uniform, standing, and filtering by using a screen, so as to obtain the product.

The invention relates to the technical field of functional compositions, in particular to an anti-wrinkle and firming functional composition containing glassine as well as a preparation method and application of the anti-wrinkle and firming functional composition containing glassine. The composition containing the botryine and having the anti-wrinkle and firming effects is prepared from the following components: 3 to 15 parts of an RS configuration botryine solution, 1 to 3 parts of a spherical PDRN compound, 0.1 to 0.5 part of a folium achilleae millefolium extract wrapped by maltodextrin and 0.5 to 1.25 parts of a sodium mannose phosphate solution, the RS-configuration glassine solution comprises R-type glassine and S-type glassine in a mass ratio of (7-8): (2-3); the spherical PDRN compound is prepared from poly (deoxyribonucleotide) (PDRN), hydrolyzed sodium hyaluronate, 1, 2-pentanediol, 1, 2-hexanediol and deionized water; the sodium mannose phosphate solution comprises sodium mannose phosphate, glycerol and water. Through the multi-target multi-layer synergistic effect of all the components, the obvious tightening and wrinkle fading effects superior to those of a single component or a conventional compound are obtained.

A method for amplifying a DNA template, comprising: a) providing a composition comprising a DNA template, an RNA polymerase, a DNA polymerase, and a deoxyribonucleotide, wherein said composition does not comprise a ribonucleotide; and b) incubating said composition in a suitable condition to allow amplification of said DNA template. Also provided is a method for priming DNA amplification from a DNA template, comprising: incubating a DNA template, an RNA polymerase and a deoxyribonucleotide in a suitable condition to allow the initiation of DNA amplification; wherein said method does not comprise adding a ribonucleotide.

The present invention discloses a novel type of gene silencing technology for modulating target nucleic acid and / or protein levels in cells, tissues, organisms, and animals. This new technology provides compositions for use in gene targeting or gene silencing applications, including the prevention and treatment of human diseases. The compositions include asymmetric, short, double-stranded RNA molecules in which the sense strand is shorter than the antisense strand. The double-stranded RNA molecules further include at least one deoxyribonucleotide monomer interspersed segment. The present invention also provides methods for using the compositions to modulate the expression or function of target genes, or for the treatment or prevention of diseases, as well as for other medical or biological applications.

A gene editing system comprising: (a) a gene editor fusion protein comprising a Cas protein and a deaminase, or a nucleic acid encoding the gene editor fusion protein, and (b) a hybrid guide nucleic acid comprising a spacer sequence, wherein the spacer sequence comprises at least one deoxyribonucleotide and a plurality of ribonucleotide is claimed. A 2’ hydroxyl group of a ribose on at least one ribonucleotide may be covalently linked to a methyl group (2’-OMe). The gene editing system for use in treating or preventing an atherosclerotic cardiovascular disease, or lowering blood low-density lipoprotein cholesterol (LDL-C) levels or lowering blood triglyceride levels is further claimed. [None]

The invention provides a tandem RNA (Ribonucleic Acid) element capable of enhancing protein synthesis efficiency. The nucleic acid construct disclosed by the invention is formed by connecting a section of sequence rich in adenine deoxynucleotide in a 5'untranslated region of a PAB1 gene derived from yeast (such as saccharomyces cerevisiae or kluyveromyces yeast), an omega sequence, an oligomeric chain [oligo (A)] n of adenine deoxynucleotide and a translation initiation codon in series. When the nucleic acid construct is applied to a yeast in-vitro biosynthesis system (such as a kluyveromyces in-vitro protein synthesis system), the protein synthesis efficiency can be remarkably improved.

This invention relates to methods for amplifying target nucleic acid. A target nucleic acid is contacted with specific primers in the presence of DNA polymerase and deoxyribonucleotide triphosphates to produce an amplification solution with a volume of 5 pl or less. The amplification solution is subjected to a denaturation temperature of 75° C.-85° C. for 1.5 second or less; and then to a polymerisation temperature of 25° C.-45° C. for 1 second or less. These denaturation and polymerisation steps are repeated to amplify the target nucleic acid. Devices and systems for performing such methods are also provided.

The application relates to the technical field of biological medicine engineering, and provides an aptamer specifically combined with chondroitin acid and application thereof. The sequence general formula of the aptamer is 5'-ATTGGCACTCCACGCATAGG-N 40 -CCTATGCGTGCTACC GTGAA-3'; wherein N is any one of A, T, G and C, the four deoxyribonucleotide bases, 40 represents the number of random bases, preferably the sequence shown in any one of SEQ ID NO. 10, SEQ ID NO. 12 and SEQ ID NO. 14, and most preferably the sequence shown in any one of SEQ ID NO. 14. The aptamer can be prepared into a chondroitin acid separation and enrichment reagent, a purification reagent, an antagonist or a neutralizer, and can also be prepared into a chondroitin acid detection reagent, a kit or a sensor, applied to the detection of DA in a drinking water body sample, and can lay a foundation for the preparation of a medicine for preventing or treating DA poisoning and the removal of DA in water bodies or aquatic products.

The present invention discloses a novel type of gene modulation technology for modulating target nucleic acid and / or protein levels in cells, tissues, organisms, and animals. This new technology provides compositions for use in gene modulation applications, including the prevention and treatment of human diseases. The compositions comprise short antisense RNA (asRNA) molecules having at least one deoxyribonucleotide monomer interspersed motif. The present invention further provides methods for using the compositions to modulate the expression or function of target genes, or for the treatment or prevention of diseases, as well as for biomedical research, disease diagnosis, and other biological applications.

The disclosure herein includes methods and compositions for nucleic acid synthesis using terminal deoxynucleotidyl transferase with a plurality of deoxyribonucleotide triphosphates each comprising a modified base having a photocleavable carbon chain moiety, which when present, enables single incorporation.

The application relates to application of clofarabine in preparation of a medicine for preventing or treating poxvirus infection. 50 The IC50 of inhibiting vaccinia virus is 0.44 muM, and the IC50 of inhibiting monkeypox virus is 0.06 muM. 50 Since the drug target points of deoxyribonucleotide large subunits of monkeypox virus, vaccinia virus, smallpox virus and other poxviruses are extremely conservative, clofarabine has the potential of broad-spectrum anti-poxvirus, and the toxic effect of clofarabine on Vero cells is extremely low. The application has important significance for prevention and treatment of poxviruses.

The invention discloses a non-crosslinked hyaluronic acid dressing based on a tea vesicle-PDRN compound as well as a preparation method and application of the non-crosslinked hyaluronic acid dressing, and relates to the field of biomedical materials. The preparation method comprises the following steps: loading polydeoxyribonucleotide (PDRN) into tea-derived extracellular vesicles (EV) through an ultrasonic-assisted co-incubation technology to obtain a PDRN-EV compound, and then dispersing the PDRN-EV compound into a non-crosslinked hyaluronic acid hydrogel matrix. The composite carrier can significantly improve the cellular uptake efficiency of PDRN, and synergistically exerts the anti-inflammatory repair characteristic of PDRN and the antioxidant activity of endogenous polyphenol of vesicles. Animal experiments show that the hydrogel accelerates epidermis reconstruction by promoting collagen deposition and hair follicle regeneration, and shortens the healing cycle of full-thickness skin defects. The problems that traditional cross-linked hydrogel is low in biotoxicity and PDRN permeable membrane delivery efficiency and the like are solved, a novel solution is provided for development of wound repair materials, and the hydrogel has clinical application potential in chronic wound treatment and medical beauty minimally invasive postoperative care.

To provide a new gene editing system capable of realizing in vivo editing.SOLUTION: An in vivo hybrid-guided gene editing system comprising: (a) a gene editor protein or a component thereof comprising a nucleic acid binding domain, or a nucleic acid encoding the gene editor protein or the component thereof; and (b) a spacer sequence comprising (i) deoxyribonucleotides and ribonucleotides comprising ribose, wherein: And (ii) a hybrid guide nucleic acid comprising a spacer sequence, wherein the 2 ' hydroxyl group of the ribose is covalently linked to a methyl group, and a binding scaffold for a gene editor protein or component thereof, wherein (a) and (b) are components comprising a pharmaceutical composition comprising a lipid nanoparticle (LNP) containing (a) or (b), wherein the LNP comprises an amino lipid, a phospholipid, a sterol, and a PEG lipid.SELECTED DRAWING: Figure 1

The invention discloses an anti-photoaging soothing and repairing composition containing camellia PDRN as well as a preparation method and application thereof, and belongs to the technical field of cosmetics. The invention provides a preparation method of camellia polydeoxyribonucleotide (PDRN), the camellia PDRN prepared by adopting the preparation method is compounded with fibroin, butyrospermum parkii butter and 4-tert-butyl cyclohexanol for use, so that the anti-light aging effect can be effectively realized, and meanwhile, the camellia polydeoxyribonucleotide also has good soothing and repairing effects; therefore, the composition can be widely applied to preparation of cosmetics, and corresponding anti-light-aging, soothing and repairing effects are achieved.